Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: A phase I/II trial

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 3019-3025

  Gioulbasanis, Ioannis ^a   Saridaki, Zacharenia ^a   Kalykaki, Antonia ^a   Vamvakas, Lambros ^a   Kalbakis, Kostas ^a   Ignatiadis, Michail ^a   Amarantidis, Kyriakos ^b   Kakolyris, Stylianos ^b   Georgoulias, Vassilis ^a   Mavroudis, Dimitris ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

Author keywords

Breast cancer; Gefitinib; Gemcitabine; Phase I II study; Vinorelbine

Indexed keywords

ANTHRACYCLINE; GEFITINIB; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LIVER TOXICITY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; TAXOIDS; VINBLASTINE;

EID: 55749103403     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ and Cardoso F: Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12: 253-270, 2007.
2. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F and Piccart MJ: Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades? Ann Oncol 13: 197-207, 2002.
3. Ershler WB: Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11: 325-335, 2006.
4. Aapro MS, Harper P, Johnson SA and Vermorken JB: Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine. Crit Rev Oncol Hematol 40: 251-263, 2001.
5. Heinemann V: Gemcitabine in metastatic breast cancer. Expert Rev Anticancer Ther 5: 429-443, 2005.
6. Chlebowski RT, Smalley RV, Weiner JM, Irwin LE, Bartolucci AA and Bateman JR: Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Study Group and The Southeastern Cancer Study Group. Br J Cancer 59: 227-230, 1989.
7. Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P et al: Combination chemotherapy single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16: 3720-3730, 1998.
8. Koroleva I, Wojtukiewicz M, Zaluski J et al: Preliminary results of a phase II randomized trial of taxotere (T) and doxorubicin (A) given in combination or sequentially as first-line chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 30a (abstr 117) 2001.
9. Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C et al: Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22: 2587-2593, 2004.
10. Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A et al: Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101: 704-712, 2004.
11. Haider K, Kornek GV, Kwasny W, Weinländer G, Valencak J, Lang F et al: Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 55: 203-211, 1999.
12. Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G et al: Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: phase II study conducted by the Hellenic cooperative Oncology Group. Ann Oncol 11: 873-875, 2000.
13. Valenza R, Leonardi V, Gebbia V and Agostara B: Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11: 495-496, 2000.
14. Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA et al: Phase II trial of biweekly administration of vinorelbine and gemcitabine in retreated advanced breast cancer. J Clin Oncol 20: 37-41, 2002.
15. Moser R, Hausmaninger H, Mlineritsch B, Steger G, Haidinger R, Thaler J et al: Gemcitabine and vinorelbine as first or second line therapy in patients with advanced breast cancer: a prospective phase II trial. Proc Am Soc Clin Oncol 20: 56b (abstr 1973) 2001.
16. Sanal SM, Gokmen E, Karabulut B and Sezgin C: Gemcitabine and Vinorelbine combination in patients with metastatic breast cancer. Breast J 8: 171-176, 2002.
17. Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagonel V et al: The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pre-treated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 78: 29-36, 2003.
18. Donadio M, Ardine M, Berruti A, Ritorto G, Fea E, Mistrangelo M et al: Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52: 147-152, 2003.
19. Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L et al: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8: 219-225, 2007.
20. Agrawal A, Gutteridge E, Gee JM, Nicholson RI and Robertson JF: Overview of tyrosine kinase inhibitors in clinical breast cancer Endocr Relat Cancer 12: 135-144, 2005.
21. Klijn JG, Berns PM, Schmitz PI and Foekens JA: The clinical significance of epidermal growth factor receptor in human breast cancer: a review of 5232 patients. Endocr Rev 13: 3-17, 1992.
22. Tsutsui S, Ohno S, Murakami S, Hachitanda Y and Oda S: Prognostic value of epidermal growth factor and its relationship to the ER status of 1029 patients with breast cancer. Breast Cancer Res and Treat 71: 67-75, 2002.
23. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F et al: Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12: 841-846, 2001.
24. Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blarney RW, Robertson JF et al: EGFR expression in operable breast cancer: is it of prognostic significance? Clin Cancer Res 10: 2578, 2004.
25. Herbst RS, Fukuoka M and Baselga J: Gefitinib, a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-965, 2004.
26. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa®), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063, 2000.
27. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa®), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
29. National Cancer Institute Common Toxicity Criteria, Version 2.0, 1999.
30. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151, 1982.
31. Lobo F, Virizuela JA, Dorta FJ, Florian J, Lomas M, Jiménez E et al: Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clin Breast Cancer 4: 46-50, 2003.
32. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y and Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 23: 1119-1125, 2004.
33. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S et al: The in vitro effect of efitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4: 83, 2004.
34. Albain K, Elledge R, Gradishar W, Hayes DF, Rowinsky E, Hudis C et al: Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res and Treat 76(suppl 1): S33 (abstr 20) 2002.
35. von Minckwitz G and Jonat W: A multicentre phase II study on gefitinib in taxane- and anthracycline - pretreated metastatic breast cancer. Breast Cancer Res and Treat 89: 165-172, 2005.
36. Winer E, Cobleigh M, Dickler M, Miller K, Fehrenbacher L, Jones C et al: Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res and Treat 76(suppl 1): S115, (abstr 445) 2002.
37. Erjala K, Raitanen M, Kulmala J and Grénman R: Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 133: 169-176, 2007.
38. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004.
39. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004.
40. Chen YM, Liu JM, Chou TY, Perng RP, Tsai CM, Whang-Peng J et al: Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 109: 1821-1828, 2007.
41. Gasparini G, Sarmiento R, Amici S, Longo R, Gattuso D, Zancan M et al: Gefitinib (ZD 1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Ann Oncol 6: 1867-1873, 2005.
42. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G et al: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94: 1604-1609, 2006.
43. Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C et al: Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA®) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 92: 1-9, 2005.
44. Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A et al: Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat 110: 127-134, 2008.
45. Pujol JL, Viens P, Rebattu P, Laurie SA, Feld R, Deneulin A et al: Gefitinib (IRESSA®) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Ocol 1: 417-424, 2006.
46. Kinkor Z: Basal-like carcinoma of the breast - the actual review and clinico-pathological correlations. Ceska Gynekol 72: 351-354, 2007.
47. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M et al: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207: 420-427, 2006.
48. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X et al: Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26: 3431-3439, 2007.